PL2364137T3 - Zawiesina farmaceutyczna - Google Patents

Zawiesina farmaceutyczna

Info

Publication number
PL2364137T3
PL2364137T3 PL09768284T PL09768284T PL2364137T3 PL 2364137 T3 PL2364137 T3 PL 2364137T3 PL 09768284 T PL09768284 T PL 09768284T PL 09768284 T PL09768284 T PL 09768284T PL 2364137 T3 PL2364137 T3 PL 2364137T3
Authority
PL
Poland
Prior art keywords
pharmaceutical suspension
pharmaceutical
suspension
Prior art date
Application number
PL09768284T
Other languages
English (en)
Inventor
Bhagwati P. Kabra
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2364137T3 publication Critical patent/PL2364137T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL09768284T 2008-12-05 2009-12-03 Zawiesina farmaceutyczna PL2364137T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12008108P 2008-12-05 2008-12-05

Publications (1)

Publication Number Publication Date
PL2364137T3 true PL2364137T3 (pl) 2017-09-29

Family

ID=41562672

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09768284T PL2364137T3 (pl) 2008-12-05 2009-12-03 Zawiesina farmaceutyczna

Country Status (17)

Country Link
US (1) US9707173B2 (pl)
EP (1) EP2364137B1 (pl)
JP (1) JP5661640B2 (pl)
AR (1) AR074423A1 (pl)
AU (1) AU2009322355B2 (pl)
CA (1) CA2745123C (pl)
CY (1) CY1119038T1 (pl)
DK (1) DK2364137T3 (pl)
ES (1) ES2630037T3 (pl)
HR (1) HRP20170959T1 (pl)
HU (1) HUE034662T2 (pl)
LT (1) LT2364137T (pl)
PL (1) PL2364137T3 (pl)
PT (1) PT2364137T (pl)
SI (1) SI2364137T1 (pl)
TW (1) TW201023912A (pl)
WO (1) WO2010065730A2 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010101989A1 (en) 2009-03-03 2010-09-10 Alcon Research, Ltd. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
CN102340993A (zh) * 2009-03-03 2012-02-01 爱尔康研究有限公司 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物
CN103140215A (zh) * 2010-07-21 2013-06-05 爱尔康研究有限公司 具有提高的溶解度特征的药物组合物
US20130303497A1 (en) 2010-08-05 2013-11-14 Conrig Pharma Aps Deuterated 5-ht1a receptor agonists
WO2014207769A1 (en) 2013-06-27 2014-12-31 Mylan Laboratories Ltd Process for the preparation of nepafenac
JP6279395B2 (ja) * 2014-05-01 2018-02-14 東亜薬品株式会社 ブリンゾラミド懸濁性点眼液組成物の製造方法
WO2017062770A1 (en) 2015-10-08 2017-04-13 Silverberg Noah Punctal plug and bioadhesives
CN108434116B (zh) * 2017-02-16 2021-05-11 人福普克药业（武汉）有限公司 贝萨罗汀软胶囊及其制备方法
WO2019012100A1 (en) 2017-07-14 2019-01-17 Janssen Pharmaceutica Nv EXTENDED ACTION FORMULATIONS
GR1009419B (el) 2017-11-07 2018-12-14 Φαρματεν Αβεε Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου
TWI798452B (zh) * 2019-06-17 2023-04-11 晶碩光學股份有限公司 隱形眼鏡產品
CN113018271B (zh) * 2019-12-25 2022-08-09 四川科瑞德制药股份有限公司 一种坦度螺酮药物组合物及其制备方法和用途
WO2021158968A1 (en) 2020-02-06 2021-08-12 Ocular Therapeutix, Inc. Compositions and methods for treating ocular diseases
CA3177005A1 (en) 2020-04-27 2021-11-04 Michael Goldstein Methods of treating allergic conjunctivitis
US20220105100A1 (en) * 2020-10-05 2022-04-07 Somerset Therapeutics, Llc Safe brinzolamide and brimonidine compositions with enhanced benzalkonium chloride content
US11850249B2 (en) 2020-10-05 2023-12-26 Somerset Therapeutics, Llc Methods of efficiently reducing intraocular pressure
CA3268120A1 (en) * 2023-05-11 2024-11-14 Akums Drugs & Pharmaceuticals Limited OPHTHALMIC FORMULATION FREE OF BENZALKONIUM CHLORIDE

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856919A (en) * 1970-06-08 1974-12-24 Burton Parsons Chemicals Inc Ophthalmic solution
US4027020A (en) 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
US3931319A (en) 1974-10-29 1976-01-06 Millmaster Onyx Corporation Capped polymers
US4409205A (en) 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4525346A (en) 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4836986A (en) 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US5037647A (en) 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
US5461081A (en) 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5145643A (en) 1990-01-05 1992-09-08 Allergan, Inc. Nonoxidative ophthalmic compositions and methods for preserving and using same
US5206267A (en) * 1991-05-09 1993-04-27 Morton Shulman Pain controlling composition and method of preparation
US5338732A (en) * 1991-06-18 1994-08-16 Bristol-Myers Squibb Company Megestrol acetate formulation
US5932572A (en) 1992-02-21 1999-08-03 Alcon Laboratories, Inc. Topical anti-glaucoma compositions
US5300287A (en) 1992-11-04 1994-04-05 Alcon Laboratories, Inc. Polymeric antimicrobials and their use in pharmaceutical compositions
ES2141775T3 (es) * 1993-04-16 2000-04-01 Wakamoto Pharma Co Ltd Composicion medicinal a base de agua termicamente gelificante reversible.
WO1996011672A1 (en) 1994-10-13 1996-04-25 Wakamoto Pharmaceutical Co., Ltd. Lyophilized preparation providing reversibly thermogelling water-base medicinal composition
CA2272308C (en) * 1996-12-13 2007-01-16 Alcon Laboratories, Inc. Use of low molecular weight amino alcohols in ophthalmic compositions
JPH10287552A (ja) * 1997-04-11 1998-10-27 Kobayashi Seiyaku Kogyo Kk 滅菌されたアシクロビル水性懸濁点眼剤及びその製造方法
NZ334572A (en) 1997-07-29 1999-08-30 Alcon Lab Inc Conditioning solutions for hard contact lens care comprising one or more galactomannans and a borate compound
CA2383971A1 (en) * 1999-09-06 2001-03-15 Hiroaki Naka Prophylactic and therapeutic medicaments for ophthalmic diseases
EP1214056B1 (en) 1999-09-24 2003-10-29 Alcon Inc. Topical suspension formulations containing ciprofloxacin and dexamethasone
WO2001087262A2 (en) * 2000-05-15 2001-11-22 Pharmacia Italia S.P.A. Stabilized steroidal suspension
JP2004504357A (ja) 2000-07-26 2004-02-12 アルコン，インコーポレイテッド ポリマー性懸濁化剤を含有しない薬学的懸濁組成物
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
US20040256749A1 (en) 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6743439B1 (en) * 2001-06-27 2004-06-01 Alcon, Inc. Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
BR0212898A (pt) 2001-09-21 2004-10-13 Alcon Inc Método de tratamento de infecções do ouvido médio
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
US20050025791A1 (en) 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
US20040235892A1 (en) 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
JP4810427B2 (ja) 2003-05-22 2011-11-09 アボット・ラボラトリーズ インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤
CA2562356A1 (en) 2004-04-08 2005-10-27 Retmed Pty Ltd Treatment of ophthalmic conditions with mineralcorticoids
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
CA2607608A1 (en) 2005-05-10 2006-11-16 Alcon, Inc. Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
WO2006121964A2 (en) * 2005-05-10 2006-11-16 Alcon, Inc. Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
US20070173538A1 (en) * 2005-12-23 2007-07-26 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20070149593A1 (en) 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20070249546A1 (en) 2006-04-22 2007-10-25 Sawaya Assad S Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them
EP2120869A2 (en) * 2006-12-18 2009-11-25 Altus Pharmaceuticals Inc. Human growth hormone formulations
MX2009012879A (es) 2007-07-20 2010-01-14 Alcon Inc Formulacion farmaceutica para suministrar a los ojos compuestos que inhiben el receptor tirosina cinasa (rtki).
PL2072564T3 (pl) 2007-12-19 2013-12-31 Sika Tech Ag Jednoskładnikowa, utwardzająca się pod wpływem wilgoci pianka polimerowa
JP5155767B2 (ja) 2008-08-04 2013-03-06 国立大学法人大阪大学 ガス検知素子
CN102340993A (zh) 2009-03-03 2012-02-01 爱尔康研究有限公司 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物

Also Published As

Publication number Publication date
TW201023912A (en) 2010-07-01
CY1119038T1 (el) 2018-01-10
US9707173B2 (en) 2017-07-18
JP5661640B2 (ja) 2015-01-28
DK2364137T3 (en) 2017-07-10
WO2010065730A3 (en) 2011-04-14
EP2364137A2 (en) 2011-09-14
EP2364137B1 (en) 2017-03-29
LT2364137T (lt) 2017-06-26
US20100144719A1 (en) 2010-06-10
ES2630037T3 (es) 2017-08-17
HUE034662T2 (en) 2018-02-28
AR074423A1 (es) 2011-01-19
JP2012511009A (ja) 2012-05-17
AU2009322355A1 (en) 2010-06-10
CA2745123A1 (en) 2010-06-10
AU2009322355B2 (en) 2015-11-05
HRP20170959T1 (hr) 2017-09-22
PT2364137T (pt) 2017-07-10
CA2745123C (en) 2018-11-13
SI2364137T1 (sl) 2017-07-31
WO2010065730A2 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
SI2364137T1 (sl) Farmacevtska suspenzija
IL237392A0 (en) Pharmaceutical combination
GB0801876D0 (en) Suspension formulations
ZA201104336B (en) Pharmaceutical compounds
GB0816372D0 (en) Pharmaceutical compounds
GB0820819D0 (en) Pharmaceutical compounds
GB0801416D0 (en) Pharmaceutical compounds
IL207378A0 (en) Pharmaceutical solid state forms
TWI365699B (en) Hanger
GB0810615D0 (en) Novel pharmaceutical
GB0816371D0 (en) Pharmaceutical compounds
EP2263891A4 (en) SUSPENSION SYSTEM
GB0812969D0 (en) Pharmaceutical compounds
PT2271618E (pt) Compostos farmacêuticos
HU0800591D0 (en) Stable pharmaceutical combination
GB0816370D0 (en) Pharmaceutical compounds
GB0913082D0 (en) Suspension device
IL208953A0 (en) Pharmaceutical combination
PL2309983T3 (pl) Farmaceutyczna postać podawania zawierająca tetrahydrobiopterynę
GB0810857D0 (en) Pharmaceutical compounds
GB0810617D0 (en) Novel pharmaceutical
HU0800414D0 (en) Pharmaceutical combination
GB0804486D0 (en) Novel pharmaceutical composituons
GB0702639D0 (en) Suspension means
GB0817006D0 (en) Pharmaceutical compounds